Clinical Trials

Advanced HER2 Negative Breast Carcinoma HRD+Breast Cancer

NCT07382713 2026-02-03

Fluzoparib Plus Famitinib Maintenance After First-Line Platinum Response in Advanced Ovarian Cancer

43 enrolled

Ovarian Neoplasms

NCT07353437 2026-01-20

Fluzoparib as Adjuvant Treatment in Patients With Germline Homologous Recombination Repair (HRR) Mutated Primary Breast Cancer (Flamenco)

334 enrolled

Breast Neoplasms

NCT05938374 2025-12-11

SPARE-03

Phase 2 Completed

52 enrolled

Phase 1/2 Not yet recruiting

NCT07141771 2025-08-26

An Umbrella Study of Recurrent, Extensive Stage Small Cell Lung Cancer Based on Molecular Typing

100 enrolled

Thoracic

SCLC, Extensive Stage

NCT06255392 2025-08-15

Randomized, Open, Controlled, Multicenter Phase III Clinical Study of Fluzoparib in Combination With Apatinib Versus Investigator-Selected Chemotherapy for HRD-Positive/HER2-negative Advanced Breast Cancer

Phase 3 Recruiting

200 enrolled

Fludzoparib" and Anti-angiogenic

NCT06208410 2025-07-25

A Clinical Study of JS105 in Combination With Other Anti-tumor Therapies in Patients With Solid Tumors

Phase 1/2 Recruiting

306 enrolled

Advanced Solid Tumors

NCT03863860 2025-07-03

A Trial of Maintenance Treatment With Fluzoparib Versus Placebo in Relapsed Ovarian Cancer Patients

Phase 3 Completed

252 enrolled

Ovarian Neoplasms

NCT06827717 2025-05-31

Phase II Study of Irinotecan Liposome (II) Combined With Temozolomide and Fluzoparib in Recurrent or Metastatic Ewing Sarcoma

29 enrolled

Sarcoma, Ewing

NCT06971211 2025-05-14

PARTOM

40 enrolled

Prostatic Neoplasms

NCT05894018 2025-05-13

RAFAS-001

32 enrolled

NCT04517357 2025-02-24

A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Phase 2 Completed

100 enrolled

Ovarian Neoplasms

NCT04869488 2025-01-24

A Trial of SHR3162 Combined With Apatinib Mesylate Tablets or SHR3162 Monotherapy in Patients With Metastatic Castration Resistant Prostate Cancer

Phase 2 Completed

93 enrolled

Phase 3 Active not recruiting

Metastatic Castration Resistant Prostate Cancer

NCT04691804 2024-12-31

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study of Fuzuloparib Combined With Abiraterone Acetate and Prednisone (AA-P) Versus Placebo Combined With AA-P as First-Line Treatment in Patients With Metastatic Castration-Resistant Prostate Cancer

496 enrolled

Metastatic Castration-Resistant Prostate Cancer (mCRPC)

NCT06541314 2024-11-27

Fluzoparib Neoadjuvant Therapy for Ovarian Cancer

48 enrolled

Ovarian Neoplasms

NCT05594095 2024-10-04

SNF Platform Study of HR+/ HER2-advanced Breast Cancer

620 enrolled

Breast Neoplasms

NCT06561022 2024-08-19

abemaSNF1/3

260 enrolled

Breast Neoplasms

NCT04228601 2024-08-16

A Study of Fluzoparib in Combination With mFOLFIRINOX in Patients With Advanced Pancreatic Cancer

Phase 1/2 Completed

39 enrolled

Advanced Pancreatic Cancer

NCT06552858 2024-08-14

Fluzoparib Combined With Dalpiciclib for Platinum Resistant Recurrent Ovarian Cancer

30 enrolled

Phase 3 Not yet recruiting

Ovarian Neoplasms

NCT06539091 2024-08-06

Fluzoparib in Combination With Apatinib Mesylate for Maintenance Therapy in Stage III-IV Ovarian Cancer

51 enrolled

Carcinoma, Ovarian Epithelial

NCT06516445 2024-07-24

SCRT Followed by Camrelizumab Combined With Fluzoparib and Chemotherapy as Neoadjuvant Therapy for LARC

33 enrolled

Colorectal Neoplasms

NCT06413992 2024-05-14

Camrelizumab Plus Fluzoparib for TP-53 Mutated Endometrial Cancer

117 enrolled

Neoplasm Metastasis, Recurrence, Endometrial Neoplasms

NCT04300114 2024-03-28

A Study of Maintenance Treatment With Fluzoparib in gBRCA/PALB2 Mutated Pancreatic Cancer Whose Disease Has Not Progressed on First Line Platinum-Based Chemotherapy

Phase 3 Terminated

5 enrolled

Pancreatic Neoplasms

NCT06254066 2024-02-12

Adebrelimab Combined With Fluzoparib in HRD-positive HR +/HER2- Advanced Breast Cancer

40 enrolled

Female Breast Cancer Patients

NCT05891093 2024-02-08

Efficacy and Safety of Fluzoparib Combined With Adjuvant Endocrine Therapy for HR+/HER2- SNF3-subtype Early Breast Cancer (BCTOP-L-A01)

Phase 3 Recruiting

766 enrolled

Breast Neoplasms

NCT05759546 2024-02-06

PARP Inhibitor With CDK4/6 Inhibitor and Endocrine Therapy in HR+/ HER2-Advanced Breast Cancer

200 enrolled

Phase 3 Not yet recruiting

Breast Cancer Metastatic

NCT06188455 2024-01-03

Maintenance Therapy After Platinum-containing Chemotherapy in Patients With Recurrent Ovarian Cancer

37 enrolled

Ovarian Neoplasms

NCT05223582 2023-12-08

Fluzoparib and Abiraterone in the preSurgery Treatment of Prostate Cancer: FAST Trial

34 enrolled

Prostatic Neoplasms

NCT06161272 2023-12-07

Fluzoparib With or Without Apatinib in Platinum-sensitive Relapsed Ovarian Cancer Previously Treated With PARPi

80 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06074692 2023-10-31

PRIMA

86 enrolled

Sarcoma, Osteosarcoma

NCT06081595 2023-10-13

Fluzoparib Combined With Apatinib in Relapsed Ovarian Carcinoma Maintenance Treatment

54 enrolled

Ovarian Neoplasms

NCT06063070 2023-10-02

First-line Maintenance Treatment With Fluzoparib Plus Bevacizumab in Advanced BRCA Wild Type Ovarian Cancer

44 enrolled

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT06055166 2023-09-26

A Clinical Study of Chemoradiotherapy Sequential Fluzoparib in Pan-solid Tumors

120 enrolled

Esophageal Squamous Cell Carcinoma

NCT04718740 2023-08-14

A Drug-drug Interaction Study Of Fluzoparib (SHR3162) on Patients With Recurrent Ovarian Cancer

33 enrolled

Ovarian Neoplasms

NCT05585281 2023-07-28

A Study of Fluzoparib Combined With QL1101 Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on Front-Line Platinum-Based Chemotherapy

25 enrolled

Ovarian Neoplasms

NCT05932264 2023-07-06

Apatinib and Fluzoparib With or Without Adebrelimab in Previously-treated TP53-mutant Advanced Non-small Cell Lung Cancer

60 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung

NCT05928780 2023-07-03

An Umbrella Trial Based on Molecular Pathway for Patients With Metastatic TNBC in First-line Treatment (FUTURE-Trop2)

Phase 1/2 Unknown

125 enrolled

Triple Negative Breast Neoplasms

NCT04774406 2023-06-06

Arterial Hypertension Related to PARP Inhibitors (ArteRIB)

Completed

2,336 enrolled

Tumor-Agnostic

Neoplasms

NCT05761470 2023-03-09

IMPARP

66 enrolled

Her-2 Negative Breast Cancer

NCT05732129 2023-02-24

The Efficacy and Safety of Fluzoparib Plus Irinotecan as Second-line Treatment in Patients With Homologous Recombination Deficiency (HRD) Metastatic Colorectal Cancer.

29 enrolled

Kenny-Caffey syndrome, Type 1

NCT03182673 2022-09-01

The Study of SHR7390 in Combination With SHR-1210 and SHR3162 in Patients With Advanced Solid Tumors

Phase 1 Terminated

31 enrolled

Solid Tumor

NCT03945604 2022-08-12

A Trial of SHR-1210 (an Anti-PD-1 Inhibitor) in Combination With Apatinib and Fluzoparib in Patients With TNBC

32 enrolled

Triple Negative Breast Neoplasms

NCT03805399 2022-08-10

FUTURE

Phase 1/2 Unknown

140 enrolled

Triple Negative Breast Neoplasms

NCT04108676 2022-07-29

Effect of Omeprazole on PK of Fluzoparib in Healthy Male Subjects

16 enrolled

Advanced Solid Tumor

NCT04355858 2022-07-26

MULAN

319 enrolled

Breast Neoplasms, Neoplasm Metastasis

NCT03075462 2022-07-01

A Study of Fluzoparib Given in Combination With Apatinib in Ovarian or Breast Cancer Patients

98 enrolled

BreastGynecologic

Ovarian Neoplasms, Triple Negative Breast Neoplasms

NCT03509636 2022-07-01

A Study of Fluzoparib（SHR-3162）in BRCA1/2-mutant Relapsed Ovarian Cancer

113 enrolled

Ovarian Neoplasms

NCT05349409 2022-06-30

A Trial of the Combination of SHR-A1811 and Fluzoparib in HER2-Expressing Cancers

212 enrolled

Advanced Solid Tumors

NCT04978012 2022-06-07

Fluzoparib and Camrelizumab in Treating Patients With R/M NPC That Progressed After First-line Chemotherapy

48 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Nasopharyngeal Neoplasms

NCT04229615 2022-04-25

A Study of Fluzoparib±Apatinib Versus Placebo Maintenance Treatment in Patients With Advanced Ovarian Cancer Following Response on First-Line Platinum-Based Chemotherapy

Phase 3 Unknown

690 enrolled